Related Experiment Videos
Radiation absorbed dose from indium-111-CYT-356
G Mardirossian1, A B Brill, K M Dwyer
1University of Massachusetts Medical Center, Nuclear Medicine Department, Worcester 01655, USA.
Summary
This study determined the radiation dose for Indium-CYT-356, an agent for prostate cancer staging. The effective dose is comparable to other Indium-111 labeled agents, with GI tract inclusion increasing it by 18%.
Area of Science:
- Nuclear Medicine
- Radiopharmaceutical Dosimetry
- Oncology
Background:
- Indium-CYT-356 is a diagnostic agent developed for prostate cancer staging.
- Human dosimetry data is essential for FDA approval and routine clinical use.
Purpose of the Study:
- To provide human dosimetry data for Indium-CYT-356.
- To support FDA approval for Indium-CYT-356 in prostate cancer staging.
Main Methods:
- Biodistribution data from prostate cancer patients receiving 111In-CYT-356.
- Organ uptake measured from sequential whole-body and planar images.
- Dose calculations using MIRD methodology and MIRDOSE 3, including GI tract modeling.
Main Results:
- Total-body dose was 0.14 mGy/MBq; effective dose ranged from 0.25-0.29 mSv/MBq.
- Highest organ doses observed in the liver (1.0 mGy/MBq), spleen (0.88 mGy/MBq), and kidneys (0.67 mGy/MBq).
Conclusions:
- Radiation dose from 111In-CYT-356 is comparable to other 111In-labeled antibodies.
- The gastrointestinal tract contributes significantly, increasing the effective dose by 18%.